4TEEN4 Pharmaceuticals GmbH
Hennigsdorf, DE · Founded 2013 · 37 employees on LinkedIn · 2 known investors
4TEEN4 develops monoclonal antibody therapeutics targeting shock and critical illness in patients. The company is advancing invobenitug (procizumab), a first-in-class treatment designed to address circulating dipeptidyl peptidase 3, a molecular driver of cardiovascular dysfunction and organ failure in shock states.
Founders & leadership
4TEEN4 Pharmaceuticals GmbH was founded in 2013 by Dr. Andreas Bergmann and Dr. Joachim Struck.
Investors · 2
Funding
SEC filings, press & company announcements- Undisclosed amountSeries CNov 2025Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does 4TEEN4 Pharmaceuticals GmbH do?
- 4TEEN4 develops monoclonal antibody therapeutics targeting shock and critical illness in patients. The company is advancing invobenitug (procizumab), a first-in-class treatment designed to address circulating dipeptidyl peptidase 3, a molecular driver of cardiovascular dysfunction and organ failure in shock states.
- Who founded 4TEEN4 Pharmaceuticals GmbH?
- 4TEEN4 Pharmaceuticals GmbH was founded by Dr. Andreas Bergmann, Dr. Joachim Struck in 2013.
- Who are 4TEEN4 Pharmaceuticals GmbH's investors?
- 4TEEN4 Pharmaceuticals GmbH's investors include Brandenburg Kapital, Görlich Gruppe.
- Where is 4TEEN4 Pharmaceuticals GmbH headquartered?
- 4TEEN4 Pharmaceuticals GmbH is headquartered in Hennigsdorf, DE.